Foghorn Therapeutics Inc. – NASDAQ:FHTX

Add to watchlist

$4.71

-0.11

-2.28%

Market closed

Open in about 5 hours

-21.88%

month

-21.88%

quarter

-27.74%

year

Market Cap	281.57M
Enterprise value	258.82M

P/E	-2.39
EV/Sales	17.18
EV/EBITDA	50.27
Price/Sales	17.22
Price/Book	2317.23
PEG ratio	-0.02
EPS	-2.2

Revenue	33.89M
EBITDA	-99.35M
Income	-92.95M
Revenue Q/Q	-4.87%
Revenue Y/Y	64.40%

Profit margin	-0.72%
Oper. margin	-0.78%
Gross margin	0%
EBIT margin	-0.78%
EBITDA margin	-293.12%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Foghorn Therapeutics Stock Forecast

M Q Y

Last Year

$14

Potential upside: 197.23%

Analysts Price target
Financials & Ratios estimates

Foghorn Therapeutics Inc. (NASDAQ:FHTX): Profit margin
Jun 2023	5.59M	-29.48M	-526.65%
Sep 2023	17.47M	-14.34M	-82.07%
Dec 2023	5.76M	-24.10M	-417.85%
Mar 2024	5.05M	-25.01M	-495.37%

Foghorn Therapeutics Inc. (NASDAQ:FHTX): Debt to assets
Jun 2023	339576000	388.92M	114.53%
Sep 2023	313423000	370.81M	118.31%
Dec 2023	285916000	363.10M	127%
Mar 2024	255004000	352.49M	138.23%

Foghorn Therapeutics Inc. (NASDAQ:FHTX): Cash Flow
Jun 2023	-32.17M	39.13M	103K
Sep 2023	-27.21M	38.42M	1.38M
Dec 2023	-27.54M	37.38M	186K
Mar 2024	-29.34M	27.09M	1.16M

Foghorn Therapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Foghorn Therapeutics
Employees

Foghorn Therapeutics Inc. (NASDAQ:FHTX): Employee count
Aug 2023	161
Sep 2023	161
Oct 2023	161
Nov 2023	161
Dec 2023	161
Jan 2024	161
Feb 2024	161
Mar 2024	116
Apr 2024	116
May 2024	116
Jun 2024	116
Jul 2024	116

Foghorn Therapeutics
Hedge Funds Holdings Q1 2023

19.72% -42.24%

of FHTX is owned by hedge funds

36 -27

hedge funds hold FHTX stock

8.20M -17.61M

shares is hold by hedge funds

FHTX hedge funds holdings changes

Foghorn Therapeutics
Insider Trading

Foghorn Therapeutics Inc. (NASDAQ:FHTX): Insider trades (number of shares)
Period	Buy	Sel
Mar 2024	0	11000
May 2024	3629829	0
Sep 2024	0	78859

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	23 Sep 2024	COSTA CARLOS officer: Chief People Officer officer: Chief People Officer	Stock Option (right to buy)	857	$3.72	$3,188
Option	23 Sep 2024	COSTA CARLOS officer: Chief People Officer officer: Chief People Officer	Common Stock	857	$3.72	$3,188
Sale	23 Sep 2024	COSTA CARLOS officer: Chief People Officer officer: Chief People Officer	Common Stock	857	$10.17	$8,716
Option	20 Sep 2024	COSTA CARLOS officer: Chief People Officer officer: Chief People Officer	Stock Option (right to buy)	35,756	$3.72	$133,012
Option	20 Sep 2024	COSTA CARLOS officer: Chief People Officer officer: Chief People Officer	Common Stock	35,756	$3.72	$133,012
Sale	20 Sep 2024	COSTA CARLOS officer: Chief People Officer officer: Chief People Officer	Common Stock	35,756	$10.04	$358,990
Option	18 Sep 2024	COSTA CARLOS officer: Chief People Officer officer: Chief People Officer	Stock Option (right to buy)	11,574	$3.72	$43,055
Option	18 Sep 2024	COSTA CARLOS officer: Chief People Officer officer: Chief People Officer	Common Stock	11,574	$3.72	$43,055
Sale	18 Sep 2024	COSTA CARLOS officer: Chief People Officer officer: Chief People Officer	Common Stock	11,574	$10.05	$116,319
Option	17 Sep 2024	COSTA CARLOS officer: Chief People Officer officer: Chief People Officer	Stock Option (right to buy)	10,272	$3.72	$38,212

FHTX insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application METHODS OF TREATING CANCER Filling date: 7 Jan 2020 Issue date: 23 Jun 2022	7 Jan 2020	23 Jun 2022
Application	Application COMPOUNDS AND USES THEREOF Filling date: 29 Jan 2020 Issue date: 21 Apr 2022	29 Jan 2020	21 Apr 2022
Application	Application COMPOUNDS AND USES THEREOF Filling date: 29 Jan 2020 Issue date: 31 Mar 2022	29 Jan 2020	31 Mar 2022
Application	Application METHODS OF TREATING CANCERS Filling date: 20 May 2021 Issue date: 17 Mar 2022	20 May 2021	17 Mar 2022
Application	Application COMPOUNDS AND USES THEREOF Filling date: 22 Jul 2021 Issue date: 17 Feb 2022	22 Jul 2021	17 Feb 2022
Application	Application METHODS OF TREATING CANCERS Filling date: 21 Nov 2019 Issue date: 20 Jan 2022	21 Nov 2019	20 Jan 2022
Application	Application METHODS OF TREATING DISORDERS Filling date: 20 Jun 2019 Issue date: 26 Aug 2021	20 Jun 2019	26 Aug 2021
Application	Application METHODS OF TREATING DISORDERS Filling date: 20 Jun 2019 Issue date: 19 Aug 2021	20 Jun 2019	19 Aug 2021
Application	Application COMPOUNDS AND USES THEREOF Filling date: 29 Jan 2021 Issue date: 29 Jul 2021	29 Jan 2021	29 Jul 2021
Application	Application COMPOUNDS AND USES THEREOF Filling date: 29 Jan 2021 Issue date: 29 Jul 2021	29 Jan 2021	29 Jul 2021

Foghorn Therapeutics
Executives

Insider	Age	Compensation
Mr. Adrian H. B. Gottschalk (1976) Pres, Chief Executive Officer & Director	49	$790,270
Dr. Carl Peter Decicco Ph.D. (1960) Chief Scientific Officer	65	$676,240
Dr. Samuel Agresta M.D., M.P.H. (1972) Chief Medical Officer	53	$511,570
Dr. Cigall Kadoch Ph.D. (1986) Founder & Director	39	$226,810
Mr. Michael J. LaCascia (1965) Chief Legal Officer	60	$119,420
Dr. Douglas G. Cole M.D. (1960) Founder & Chairman	65	$16,030

Foghorn Therapeutics
Latest News

Monday, 16 December 2024
07:00	Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities	globenewswire.com
Thursday, 12 December 2024
10:36	After Plunging -30.17% in 4 Weeks, Here's Why the Trend Might Reverse for Foghorn Therapeutics (FHTX)	zacks.com
Friday, 29 November 2024
13:00	Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why	zacks.com
Monday, 25 November 2024
10:56	Wall Street Analysts See a 104.08% Upside in Foghorn Therapeutics (FHTX): Can the Stock Really Move This High?	zacks.com
Tuesday, 12 November 2024
07:54	Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences	globenewswire.com
Monday, 4 November 2024
18:31	Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates	zacks.com
16:05	Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update	globenewswire.com
Thursday, 10 October 2024
07:00	Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors	globenewswire.com
Tuesday, 1 October 2024
07:00	Foghorn Therapeutics to Participate in the BMO Oncology Summit	globenewswire.com
Monday, 16 September 2024
05:15	Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength?	zacks.com
Tuesday, 3 September 2024
07:00	Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer	globenewswire.com
Monday, 2 September 2024
10:55	Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 81.16%: Read This Before Placing a Bet	zacks.com
Wednesday, 28 August 2024
07:00	Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September	globenewswire.com
Friday, 16 August 2024
10:55	Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 121.77%: Here's is How to Trade	zacks.com
09:20	5 Small Drug Stocks to Buy as Innovation Reaches Peak	zacks.com
Thursday, 8 August 2024
09:10	Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Tops Revenue Estimates	zacks.com
07:00	Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update	globenewswire.com
Tuesday, 28 May 2024
07:00	Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June	globenewswire.com
Wednesday, 22 May 2024
18:21	Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline	globenewswire.com
Monday, 20 May 2024
07:58	Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants	globenewswire.com
Monday, 6 May 2024
09:11	Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates	Zacks Investment Research
Tuesday, 2 April 2024
10:56	Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 105.75% as Wall Street Analysts Expect?	Zacks Investment Research
Tuesday, 26 March 2024
07:00	Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting	GlobeNewsWire
Wednesday, 13 March 2024
13:00	Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's What You Should Know	Zacks Investment Research
10:56	Wall Street Analysts Predict a 124.31% Upside in Foghorn Therapeutics Inc. (FHTX): Here's What You Should Know	Zacks Investment Research
Thursday, 7 March 2024
09:21	Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates	Zacks Investment Research
Tuesday, 5 March 2024
16:48	Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909	GlobeNewsWire
Monday, 12 February 2024
03:46	Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last?	Zacks Investment Research
Friday, 9 February 2024
11:05	Foghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Development	Zacks Investment Research
Tuesday, 26 December 2023
13:31	Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's Why	Zacks Investment Research

Ideas & Opinions

Seeking Alpha 16 Aug 2023

Foghorn Therapeutics: Ifs, Buts, And Clinical Holds
Seeking Alpha 10 Oct 2022

Foghorn Therapeutics: Selling For Less Than Cash Value
Seeking Alpha 2 Jun 2022

Foghorn: Big Pharma Interest, Resolvable Clinical Hold Equals Opportunity

Frequently Asked Questions (FAQ)

What's the price of Foghorn Therapeutics stock today?

One share of Foghorn Therapeutics stock can currently be purchased for approximately $4.71.
When is Foghorn Therapeutics's next earnings date?

Unfortunately, Foghorn Therapeutics's (FHTX) next earnings date is currently unknown.
Does Foghorn Therapeutics pay dividends?

No, Foghorn Therapeutics does not pay dividends.
How much money does Foghorn Therapeutics make?

Foghorn Therapeutics has a market capitalization of 281.57M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 77.63% to 34.16M US dollars.
What is Foghorn Therapeutics's stock symbol?

Foghorn Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "FHTX".
What is Foghorn Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Foghorn Therapeutics?

Shares of Foghorn Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Foghorn Therapeutics's key executives?
Foghorn Therapeutics's management team includes the following people:
- Mr. Adrian H. B. Gottschalk Pres, Chief Executive Officer & Director(age: 49, pay: $790,270)
- Dr. Carl Peter Decicco Ph.D. Chief Scientific Officer(age: 65, pay: $676,240)
- Dr. Samuel Agresta M.D., M.P.H. Chief Medical Officer(age: 53, pay: $511,570)
- Dr. Cigall Kadoch Ph.D. Founder & Director(age: 39, pay: $226,810)
- Mr. Michael J. LaCascia Chief Legal Officer(age: 60, pay: $119,420)
- Dr. Douglas G. Cole M.D. Founder & Chairman(age: 65, pay: $16,030)
Is Foghorn Therapeutics founder-led company?

Yes, Foghorn Therapeutics is a company led by its founders Dr. Cigall Kadoch Ph.D. and Dr. Douglas G. Cole M.D..
How many employees does Foghorn Therapeutics have?

As Jul 2024, Foghorn Therapeutics employs 116 workers.
When Foghorn Therapeutics went public?

Foghorn Therapeutics Inc. is publicly traded company for more then 4 years since IPO on 23 Oct 2020.
What is Foghorn Therapeutics's official website?

The official website for Foghorn Therapeutics is foghorntx.com.
Where are Foghorn Therapeutics's headquarters?

Foghorn Therapeutics is headquartered at 500 Technology Square, Cambridge, MA.
How can i contact Foghorn Therapeutics?

Foghorn Therapeutics's mailing address is 500 Technology Square, Cambridge, MA and company can be reached via phone at +61 75863100.
What is Foghorn Therapeutics stock forecast & price target?

Based on 3 Wall Street analysts` predicted price targets for Foghorn Therapeutics in the last 12 months, the avarage price target is $14. The average price target represents a 197.23% change from the last price of $4.71.

Foghorn Therapeutics Inc.

foghorntx.com

Exchange:

NASDAQ

Full time employees:

116

Industry:

Biotechnology

Sector:

Healthcare

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

+61 75863100

500 Technology Square
Cambridge, MA 02139

CIK: 0001822462
ISIN: US3441741077
CUSIP: 344174107